Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

NCT01247922 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
4
Enrollment
INDUSTRY
Sponsor class

Stopped In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, the companion trial, OSI-774-206 has been stopped

Conditions

Interventions

Sponsor

OSI Pharmaceuticals